Analysis of Amount, Size, Protein Phenotype and Molecular Content of Circulating Extracellular Vesicles Identifies New Biomarkers in Multiple Myeloma
© 2021 Laurenzana et al..
INTRODUCTION: Extracellular vesicles (EVs) are naturally secreted cellular lipid bilayer particles, which carry a selected molecular content. Owing to their systemic availability and their role in tumor pathogenesis, circulating EVs (cEVs) can be a valuable source of new biomarkers useful for tumor diagnosis, prognostication and monitoring. However, a precise approach for isolation and characterization of cEVs as tumor biomarkers, exportable in a clinical setting, has not been conclusively established.
METHODS: We developed a novel and laboratory-made procedure based on a bench centrifuge step which allows the isolation of serum cEVs suitable for subsequent characterization of their size, amount and phenotype by nanoparticle tracking analysis, microscopy and flow cytometry, and for nucleic acid assessment by digital PCR.
RESULTS: Applied to blood from healthy subjects (HSs) and tumor patients, our approach permitted from a small volume of serum (i) the isolation of a great amount of EVs enriched in small vesicles free from protein contaminants; (ii) a suitable and specific cell origin identification of EVs, and (iii) nucleic acid content assessment. In clonal plasma cell malignancy, like multiple myeloma (MM), our approach allowed us to identify specific MM EVs, and to characterize their size, concentration and microRNA content allowing significant discrimination between MM and HSs. Finally, EV associated biomarkers correlated with MM clinical parameters.
CONCLUSION: Overall, our cEV based procedure can play an important role in malignancy biomarker discovery and then in real-time tumor monitoring using minimal invasive samples. From a practical point of view, it is smart (small sample volume), rapid (two hours), easy (no specific expertise required) and requirements are widely available in clinical laboratories.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
International journal of nanomedicine - 16(2021) vom: 17., Seite 3141-3160 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Laurenzana, Ilaria [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 24.05.2021 Date Revised 02.04.2024 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.2147/IJN.S303391 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325460639 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325460639 | ||
| 003 | DE-627 | ||
| 005 | 20240402232943.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2147/IJN.S303391 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1360.xml |
| 035 | |a (DE-627)NLM325460639 | ||
| 035 | |a (NLM)33994784 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Laurenzana, Ilaria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Analysis of Amount, Size, Protein Phenotype and Molecular Content of Circulating Extracellular Vesicles Identifies New Biomarkers in Multiple Myeloma |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.05.2021 | ||
| 500 | |a Date Revised 02.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 Laurenzana et al. | ||
| 520 | |a INTRODUCTION: Extracellular vesicles (EVs) are naturally secreted cellular lipid bilayer particles, which carry a selected molecular content. Owing to their systemic availability and their role in tumor pathogenesis, circulating EVs (cEVs) can be a valuable source of new biomarkers useful for tumor diagnosis, prognostication and monitoring. However, a precise approach for isolation and characterization of cEVs as tumor biomarkers, exportable in a clinical setting, has not been conclusively established | ||
| 520 | |a METHODS: We developed a novel and laboratory-made procedure based on a bench centrifuge step which allows the isolation of serum cEVs suitable for subsequent characterization of their size, amount and phenotype by nanoparticle tracking analysis, microscopy and flow cytometry, and for nucleic acid assessment by digital PCR | ||
| 520 | |a RESULTS: Applied to blood from healthy subjects (HSs) and tumor patients, our approach permitted from a small volume of serum (i) the isolation of a great amount of EVs enriched in small vesicles free from protein contaminants; (ii) a suitable and specific cell origin identification of EVs, and (iii) nucleic acid content assessment. In clonal plasma cell malignancy, like multiple myeloma (MM), our approach allowed us to identify specific MM EVs, and to characterize their size, concentration and microRNA content allowing significant discrimination between MM and HSs. Finally, EV associated biomarkers correlated with MM clinical parameters | ||
| 520 | |a CONCLUSION: Overall, our cEV based procedure can play an important role in malignancy biomarker discovery and then in real-time tumor monitoring using minimal invasive samples. From a practical point of view, it is smart (small sample volume), rapid (two hours), easy (no specific expertise required) and requirements are widely available in clinical laboratories | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a digital PCR | |
| 650 | 4 | |a extracellular vesicles | |
| 650 | 4 | |a flow cytometry | |
| 650 | 4 | |a hematological malignancies | |
| 650 | 4 | |a nanoparticle tracking analysis | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 700 | 1 | |a Trino, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Lamorte, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Girasole, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Dinarelli, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a De Stradis, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Grieco, Vitina |e verfasserin |4 aut | |
| 700 | 1 | |a Maietti, Maddalena |e verfasserin |4 aut | |
| 700 | 1 | |a Traficante, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Statuto, Teodora |e verfasserin |4 aut | |
| 700 | 1 | |a Villani, Oreste |e verfasserin |4 aut | |
| 700 | 1 | |a Musto, Pellegrino |e verfasserin |4 aut | |
| 700 | 1 | |a Sgambato, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a De Luca, Luciana |e verfasserin |4 aut | |
| 700 | 1 | |a Caivano, Antonella |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of nanomedicine |d 2006 |g 16(2021) vom: 17., Seite 3141-3160 |w (DE-627)NLM16062035X |x 1178-2013 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2021 |g day:17 |g pages:3141-3160 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2147/IJN.S303391 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2021 |b 17 |h 3141-3160 | ||